Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients.

Trial Profile

Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Diabetic complications; Dyslipidaemias; Metabolic syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genfit
  • Most Recent Events

    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Sep 2012 Planned end date changed from 31 May 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top